CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series
| Autor: | Lisa Lyngsie Hjalgrim, Georg C. Schwabe, Peter Lang, Wilhelm Woessmann, Daniel Steinbach, Holger Hebart, Edita Kabickova, Stephanie Ruf |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Adolescent Central nervous system Vinblastine 03 medical and health sciences Young Adult 0302 clinical medicine Central Nervous System Diseases hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Anaplastic lymphoma kinase Humans Anaplastic Lymphoma Kinase Molecular Targeted Therapy Brentuximab vedotin Child Anaplastic large-cell lymphoma Crizotinib business.industry Hematology medicine.disease Prognosis Transplantation Survival Rate medicine.anatomical_structure 030220 oncology & carcinogenesis Child Preschool Pediatrics Perinatology and Child Health Disease Progression Lymphoma Large-Cell Anaplastic Female Stem cell Neoplasm Recurrence Local business 030215 immunology medicine.drug |
| Zdroj: | Pediatric bloodcancer. 65(6) |
| ISSN: | 1545-5017 |
| Popis: | Vinblastine and targeted therapies induce remissions in patients with relapsed or progressive anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). Central nervous system (CNS) prophylaxis often is not included during re-induction in CNS-negative relapse patients. We report on five patients with progressive or early relapsed ALK-positive ALCL who developed CNS progression during re-induction with vinblastine, crizotinib, or brentuximab vedotin given for bridging to allogeneic blood stem cell transplantation. These observations suggest that CNS prophylaxis should be considered in ALCL patients suffering progression during initial therapy who receive re-induction using agents with limited CNS penetration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text